Hans Knoop
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hans Knoop has a total of 929 co-authors. Here are the top co-authors by number of shared publications:
Gijs Bleijenberg
Radboudumc Department of Medical Psychology Nijmegen the Netherlands
49 shared publicationsG. Bleijenberg
Radboud University Medical Center, Nijmegen, The Netherlands
17 shared publications- Gijs Bleijenberg
Radboud Expert Centre for Q Fever, Radboud university medical center Nijmegen, the Netherlands
10 shared publications Judith B. Prins
Department of Medical Psychology Radboud University Medical Center, Radboud, Institute for Health Sciences Nijmegen The Netherlands
10 shared publications- Hanneke Poort
Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA
9 shared publications - Jos W. M. van der Meer
Radboud University Medical Center, Nijmegen, The Netherlands
8 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1) , 154
Fatigue: assess and address it
Severe fatigue is highly prevalent in patients across different medical conditions and can only be partially explained by disease-specific factors. Also, fatigue is often seen by patients as one of the most disabling symptoms. Despite its substantial impact, fatigue is often not systematically discussed in clinical practice. Effective generic treatments exist for patients with severe fatigue. When fatigue is not assessed, patients may be withhold the opportunity to get advice on how to manage fatigue or receive effective interventions to achieve meaningful improvement. Therefore, designated health care professionals involved in patient care should be able to recognize and address fatigue as a key patient-reported outcome.
- 25 August 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1) , 154
Open AccessFatigue: assess and address it
Severe fatigue is highly prevalent in patients across different medical conditions and can only be partially explained by disease-specific factors. Also, fatigue is often seen by patients as one of the most disabling symptoms. Despite its substantial impact, fatigue is often not systematically discussed in clinical practice. Effective generic treatments exist for patients with severe fatigue. When fatigue is not assessed, patients may be withhold the opportunity to get advice on how to manage fatigue or receive effective interventions to achieve meaningful improvement. Therefore, designated health care professionals involved in patient care should be able to recognize and address fatigue as a key patient-reported outcome.
- Open Access
- 28 July 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
TIRELESS study protocol: non-inferiority study of nurse-led web-based cognitive behavioral therapy for cancer-related fatigue in patients with incurable cancer
Fatigue is a prevalent and debilitating symptom for patients with incurable cancer. Cognitive behavioral therapy (CBT) can significantly reduce cancer-rela
- 28 July 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessTIRELESS study protocol: non-inferiority study of nurse-led web-based cognitive behavioral therapy for cancer-related fatigue in patients with incurable cancer
Fatigue is a prevalent and debilitating symptom for patients with incurable cancer. Cognitive behavioral therapy (CBT) can significantly reduce cancer-rela
- Open Access
- 20 November 2025
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 201, 112467
Which cognitive-behavioural factors play a role in the reduction of post-COVID-19 fatigue following cognitive behavioural therapy and care as usual? A secondary analysis of the ReCOVer study
- 20 November 2025
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 201, 112467
Open AccessWhich cognitive-behavioural factors play a role in the reduction of post-COVID-19 fatigue following cognitive behavioural therapy and care as usual? A secondary analysis of the ReCOVer study
- Open Access
- 9 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (3) , 693-703
Bayesian adaptive randomized trial of blended cognitive behavioral therapy for severe fatigue in stable diffuse glioma
Abstract Background: While severe fatigue is common in patients with diffuse glioma, no evidence-based treatment is currently available. The objective of this RCT was to evaluate the efficacy of blended cognitive behavioral therapy (bCBT) for severe fatigue. Methods: Severely fatigued patients (Checklist Individual Strength, fatigue-severity subscale [CIS-fatigue] ≥ 35) with diffuse glioma and stable disease were randomized to 12 weeks of bCBT or a waiting list condition (WLC). The primary endpoint was fatigue severity 2 weeks after intervention. This Bayesian adaptive trial included prespecified interim analyses for efficacy at n = 40, 50, 60, 70, and 80. Secondary outcomes—health-related quality of life (HRQoL), anxiety, future uncertainty, and depression—were assessed at 2 and 12 weeks after intervention. Results: The trial was stopped for efficacy at the first interim analysis. Of 47 patients randomized, 40 patients reached the primary endpoint (mean age 53 years, 47% female). The posterior probability that CIS-fatigue scores were lower with bCBT than with WLC was 99.94%, with a large standardized effect size (Cohen’s d) of 1.12 [95% CI: 0.43–1.81]. At 2 weeks after intervention, 68% of patients were no longer severely fatigued after bCBT, compared to 24% in WLC. At 12 weeks follow-up, fatigue was still significantly lower in the bCBT group compared to WLC (d = 1.22). bCBT also demonstrated beneficial effects (d = 0.42-1.19) on anxiety, HRQoL, and future uncertainty. Conclusions: bCBT significantly reduces fatigue and improves anxiety and HRQoL in patients with diffuse glioma. These findings enable evidence-based supportive care strategies for reducing fatigue and enhancing HRQoL in this population.
- 9 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (3) , 693-703
Open AccessBayesian adaptive randomized trial of blended cognitive behavioral therapy for severe fatigue in stable diffuse glioma
Abstract Background: While severe fatigue is common in patients with diffuse glioma, no evidence-based treatment is currently available. The objective of this RCT was to evaluate the efficacy of blended cognitive behavioral therapy (bCBT) for severe fatigue. Methods: Severely fatigued patients (Checklist Individual Strength, fatigue-severity subscale [CIS-fatigue] ≥ 35) with diffuse glioma and stable disease were randomized to 12 weeks of bCBT or a waiting list condition (WLC). The primary endpoint was fatigue severity 2 weeks after intervention. This Bayesian adaptive trial included prespecified interim analyses for efficacy at n = 40, 50, 60, 70, and 80. Secondary outcomes—health-related quality of life (HRQoL), anxiety, future uncertainty, and depression—were assessed at 2 and 12 weeks after intervention. Results: The trial was stopped for efficacy at the first interim analysis. Of 47 patients randomized, 40 patients reached the primary endpoint (mean age 53 years, 47% female). The posterior probability that CIS-fatigue scores were lower with bCBT than with WLC was 99.94%, with a large standardized effect size (Cohen’s d) of 1.12 [95% CI: 0.43–1.81]. At 2 weeks after intervention, 68% of patients were no longer severely fatigued after bCBT, compared to 24% in WLC. At 12 weeks follow-up, fatigue was still significantly lower in the bCBT group compared to WLC (d = 1.22). bCBT also demonstrated beneficial effects (d = 0.42-1.19) on anxiety, HRQoL, and future uncertainty. Conclusions: bCBT significantly reduces fatigue and improves anxiety and HRQoL in patients with diffuse glioma. These findings enable evidence-based supportive care strategies for reducing fatigue and enhancing HRQoL in this population.
- Open Access
- 28 October 2025
- Published by Elsevier in EBioMedicine
- Vol. 121, 105970
Immunological associations in post-infective fatigue syndromes including Long COVID—a systematic review and meta-analysis
- 28 October 2025
- Published by Elsevier in EBioMedicine
- Vol. 121, 105970
Open AccessImmunological associations in post-infective fatigue syndromes including Long COVID—a systematic review and meta-analysis
- Open Access
- 3 October 2025
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 199, 112401
The association of fatigue and pain with cognitive test performance in patients with myalgic encephalomyelitis/chronic fatigue syndrome
- 3 October 2025
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 199, 112401
Open AccessThe association of fatigue and pain with cognitive test performance in patients with myalgic encephalomyelitis/chronic fatigue syndrome
- Open Access
- 19 September 2025
- Published by Wiley in Psycho-Oncology
- Vol. 34 (9) , e70282
Cognitive Behavioral Therapy for Cancer‐Related Fatigue: A Comparison Between Patients Treated With Curative Intent and Patients With Advanced Cancer
Background: Cancer‐related fatigue (CRF) is prevalent in patients who have been treated with curative intent and patients with advanced cancer. Cognitive behavioral therapy (CBT) has been shown effective in reducing CRF in both groups. Aims: To compare both groups with respect to: (1) pre‐treatment levels of fatigue and fatigue‐perpetuating cognitive‐behavioral factors; (2) the magnitude of the effect of CBT on fatigue; and (3) mediators of the treatment response. Methods: Data of four randomized controlled trials testing the efficacy of CBT for CRF were pooled, three in patients treated with curative intent ( n = 249), and one in patients with advanced cancer ( n = 134). Baseline characteristics were compared with ANCOVAs. Moderation analysis was used to investigate whether the treatment effect differed between groups. With moderated mediation analyses differences in the mechanisms by which CBT reduces fatigue were evaluated. Results: The two groups differed significantly at baseline on fatigue‐perpetuating factors, but not on fatigue severity. Patients with advanced cancer reported a smaller decrease in fatigue severity following CBT than patients treated with curative intent ( p = 0.022). The multivariate moderated mediation analysis showed a larger decrease in fatigue catastrophizing in patients treated with curative intent than in patients with advanced cancer. Conclusion: CBT for CRF has less effect on catastrophizing, a known fatigue‐perpetuating factor and mediator of the effect of CBT, and fatigue severity in patients with advanced cancer. Further research has to determine if the effectiveness of CBT for CRF in advanced cancer patients can be improved.
- 19 September 2025
- Published by Wiley in Psycho-Oncology
- Vol. 34 (9) , e70282
Open AccessCognitive Behavioral Therapy for Cancer‐Related Fatigue: A Comparison Between Patients Treated With Curative Intent and Patients With Advanced Cancer
Background: Cancer‐related fatigue (CRF) is prevalent in patients who have been treated with curative intent and patients with advanced cancer. Cognitive behavioral therapy (CBT) has been shown effective in reducing CRF in both groups. Aims: To compare both groups with respect to: (1) pre‐treatment levels of fatigue and fatigue‐perpetuating cognitive‐behavioral factors; (2) the magnitude of the effect of CBT on fatigue; and (3) mediators of the treatment response. Methods: Data of four randomized controlled trials testing the efficacy of CBT for CRF were pooled, three in patients treated with curative intent ( n = 249), and one in patients with advanced cancer ( n = 134). Baseline characteristics were compared with ANCOVAs. Moderation analysis was used to investigate whether the treatment effect differed between groups. With moderated mediation analyses differences in the mechanisms by which CBT reduces fatigue were evaluated. Results: The two groups differed significantly at baseline on fatigue‐perpetuating factors, but not on fatigue severity. Patients with advanced cancer reported a smaller decrease in fatigue severity following CBT than patients treated with curative intent ( p = 0.022). The multivariate moderated mediation analysis showed a larger decrease in fatigue catastrophizing in patients treated with curative intent than in patients with advanced cancer. Conclusion: CBT for CRF has less effect on catastrophizing, a known fatigue‐perpetuating factor and mediator of the effect of CBT, and fatigue severity in patients with advanced cancer. Further research has to determine if the effectiveness of CBT for CRF in advanced cancer patients can be improved.
- Open Access
- 7 August 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e53080
User Experiences Among Patients and Health Care Professionals Who Participated in a Randomized Controlled Trial of E-nergEYEze, a Vision-Specific eHealth Intervention to Reduce Fatigue in Adults With Visual Impairment: Mixed Methods Study
Background: Fatigue is a common symptom occurring in individuals with visual impairment (VI). Feeling fatigued has a strong impact on an individual’s well-being, with profound consequences. Cognitive and emotional functioning, social roles, and participation are negatively affected in severely fatigued individuals with VI. Therefore, we developed E-nergEYEze, a blended vision-specific eHealth intervention based on cognitive behavioral therapy and self-management to reduce fatigue severity in adults with VI. Objective: We aimed to report the experience of patients and professionals with E-nergEYEze. To complement cost-effectiveness outcomes, the user experiences from both perspectives were considered relevant for a better understanding of the intervention uptake. Methods: E-nergEYEze was studied in a randomized controlled trial. User experiences of participants with VI and severe fatigue (51/98, 52%; median age 58.0, IQR 53.0-65.0 years; female participants: 32/51, 63%), who were randomized to the intervention group, and professionals (n=11), who provided blended support, were evaluated. The Dutch Mental Health Care Thermometer questionnaire and a therapist evaluation were used and analyzed using mixed methods. A focus group meeting with social workers (4/7, 57%), a computer trainer (1/7, 14%), and psychologists (2/7, 29%) was held for more in-depth information. The eHealth platform provided data on user engagement from both perspectives. Results: E-nergEYEze was completed by 63% (32/51) of patients for more than 80% of the module steps. Overall, results on user engagement showed that a median 89% (IQR 45%-100%) of all assigned module steps were completed, with all modules being completed by at least 50% (37/51) of the patients. Completion of the intervention was related to the presence of digital proficiency; having the appropriate expectations; content that matches personal preferences and life context; and the absence of impeding personal circumstances, mental health issues, or other concurrent rehabilitation programs. The intervention was given a median grade of 7.0 out of 10.0 (IQR 6.0-8.0), and 87% (39/45) of the patients reported that they would recommend E-nergEYEze to others. However, improvements in the frequency and quality of guidance were considered highly relevant. Professionals reported that E-nergEYEze required patients’ self-efficacy, motivation, and digital skills; therefore, preselection was seen as essential. Professionals’ affinity with eHealth was considered important to provide appropriate remote support. Conclusions: eHealth provides treatment opportunities for individuals with VI for which guidance is considered highly relevant. During participation in E-nergEYEze, patients were engaged, internalized personally relevant topics, and made use of the benefits of eHealth. More attention to the suitability of patients and training of professionals for providing remote support is considered essential. These user experiences underlined the potential of E-nergEYEze to reduce fatigue severity in adults with VI and provided valuable insights to learn from and optimize E-nergEYEze. Trial Registration: International Clinical Trials Registry Platform (ICTRP) NL7764; https://tinyurl.com/32b3xt74
- 7 August 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e53080
Open AccessUser Experiences Among Patients and Health Care Professionals Who Participated in a Randomized Controlled Trial of E-nergEYEze, a Vision-Specific eHealth Intervention to Reduce Fatigue in Adults With Visual Impairment: Mixed Methods Study
Background: Fatigue is a common symptom occurring in individuals with visual impairment (VI). Feeling fatigued has a strong impact on an individual’s well-being, with profound consequences. Cognitive and emotional functioning, social roles, and participation are negatively affected in severely fatigued individuals with VI. Therefore, we developed E-nergEYEze, a blended vision-specific eHealth intervention based on cognitive behavioral therapy and self-management to reduce fatigue severity in adults with VI. Objective: We aimed to report the experience of patients and professionals with E-nergEYEze. To complement cost-effectiveness outcomes, the user experiences from both perspectives were considered relevant for a better understanding of the intervention uptake. Methods: E-nergEYEze was studied in a randomized controlled trial. User experiences of participants with VI and severe fatigue (51/98, 52%; median age 58.0, IQR 53.0-65.0 years; female participants: 32/51, 63%), who were randomized to the intervention group, and professionals (n=11), who provided blended support, were evaluated. The Dutch Mental Health Care Thermometer questionnaire and a therapist evaluation were used and analyzed using mixed methods. A focus group meeting with social workers (4/7, 57%), a computer trainer (1/7, 14%), and psychologists (2/7, 29%) was held for more in-depth information. The eHealth platform provided data on user engagement from both perspectives. Results: E-nergEYEze was completed by 63% (32/51) of patients for more than 80% of the module steps. Overall, results on user engagement showed that a median 89% (IQR 45%-100%) of all assigned module steps were completed, with all modules being completed by at least 50% (37/51) of the patients. Completion of the intervention was related to the presence of digital proficiency; having the appropriate expectations; content that matches personal preferences and life context; and the absence of impeding personal circumstances, mental health issues, or other concurrent rehabilitation programs. The intervention was given a median grade of 7.0 out of 10.0 (IQR 6.0-8.0), and 87% (39/45) of the patients reported that they would recommend E-nergEYEze to others. However, improvements in the frequency and quality of guidance were considered highly relevant. Professionals reported that E-nergEYEze required patients’ self-efficacy, motivation, and digital skills; therefore, preselection was seen as essential. Professionals’ affinity with eHealth was considered important to provide appropriate remote support. Conclusions: eHealth provides treatment opportunities for individuals with VI for which guidance is considered highly relevant. During participation in E-nergEYEze, patients were engaged, internalized personally relevant topics, and made use of the benefits of eHealth. More attention to the suitability of patients and training of professionals for providing remote support is considered essential. These user experiences underlined the potential of E-nergEYEze to reduce fatigue severity in adults with VI and provided valuable insights to learn from and optimize E-nergEYEze. Trial Registration: International Clinical Trials Registry Platform (ICTRP) NL7764; https://tinyurl.com/32b3xt74
- Open Access
- 31 July 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (1) , 149-161
Self-reported physical functioning and physical fitness in glioma patients
Background: Knowledge about glioma patients’ physical functioning and physical fitness throughout the disease trajectory is limited. We analyzed self-reported functioning and fitness in a large sample of glioma patients preoperatively and after primary treatment. Methods: We used the physical functioning subscale of the 36-Item Short Form Health Survey (SF36) and three questions about physical fitness from the Checklist of Individual Strength (CIS20). Scores were compared to age-, sex-, and education-matched population controls, preoperatively and after treatment. In patients with repeated assessments, changes over time were analyzed. Correlations between patient, disease, and treatment characteristics and functioning and fitness at both time points, and with change over time, were explored. Analyses were performed separately for World Health Organization grade II, III, and IV glioma. Results: Grade III patients had significantly lower functioning than controls, both preoperatively and after treatment, and declined over time. No significant differences with controls were found for grade II and IV patients, or for fitness. Grade II patients reported better functioning than grade III and IV preoperatively and better than grade III after treatment. Lower Karnofsky Performance Status was generally related to lower functioning and fitness, while older age, female sex, and lower education appeared in subgroup analyses. Age, neurological disabilities and tumor histology were associated with changes over time. Conclusions: Grade III glioma patients showed poorer functioning than population controls, which declined over time. Grade II patients reported better outcomes than the other subgroups, although individual variability was high. These findings highlight the need for personalized approaches addressing functioning and fitness in glioma.
- 31 July 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (1) , 149-161
Open AccessSelf-reported physical functioning and physical fitness in glioma patients
Background: Knowledge about glioma patients’ physical functioning and physical fitness throughout the disease trajectory is limited. We analyzed self-reported functioning and fitness in a large sample of glioma patients preoperatively and after primary treatment. Methods: We used the physical functioning subscale of the 36-Item Short Form Health Survey (SF36) and three questions about physical fitness from the Checklist of Individual Strength (CIS20). Scores were compared to age-, sex-, and education-matched population controls, preoperatively and after treatment. In patients with repeated assessments, changes over time were analyzed. Correlations between patient, disease, and treatment characteristics and functioning and fitness at both time points, and with change over time, were explored. Analyses were performed separately for World Health Organization grade II, III, and IV glioma. Results: Grade III patients had significantly lower functioning than controls, both preoperatively and after treatment, and declined over time. No significant differences with controls were found for grade II and IV patients, or for fitness. Grade II patients reported better functioning than grade III and IV preoperatively and better than grade III after treatment. Lower Karnofsky Performance Status was generally related to lower functioning and fitness, while older age, female sex, and lower education appeared in subgroup analyses. Age, neurological disabilities and tumor histology were associated with changes over time. Conclusions: Grade III glioma patients showed poorer functioning than population controls, which declined over time. Grade II patients reported better outcomes than the other subgroups, although individual variability was high. These findings highlight the need for personalized approaches addressing functioning and fitness in glioma.
- Open Access
- 26 June 2025
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 48 (12)
Low dose amitriptyline versus cognitive behavioral therapy for insomnia in patients with medical comorbidity: results of a randomized controlled multicenter non inferiority trial
Study objectives: In a randomized controlled non-inferiority trial, we aimed to determine whether low dose Amitriptyline (AM), which is often used off-label, is a safe and effective alternative to cognitive behavioral therapy for insomnia (CBT-I) in the treatment of insomnia among patients with insomnia and medical comorbidity. Methods: A total of 187 participants with insomnia and medical comorbidity were randomly allocated to either: 1) 12 weeks of AM, 10-20 mg (n = 93), or 2) 12 weeks of group CBT-I, 7 sessions (n = 94). Assessments took place at baseline, 6 and 12 weeks after start of treatment. The primary non-inferiority outcome was insomnia severity (Insomnia Severity Index; ISI) at 12 weeks. Results: Based on a non-inferiority margin of four points on the ISI, AM was non-inferior to CBT-I at 12 weeks of treatment (mean difference of 1.1 points; 95% CI -0.5 to 2.8). Secondary analyses showed that significantly more CBT-I participants reached a clinical response (≥ 8-point reduction on the ISI) than AM participants (58% versus 41%, p=.02). AM participants reported more side-effects (mostly anticholinergic) at 12 weeks treatment (p<.001) than participants who received CBT-I. After discontinuation 68% of the AM participants reported worsening of sleep. In 12% of them this worsening was temporarily. Conclusions: With a liberal non-inferiority margin, AM is non-inferior to CBT-I in reducing insomnia severity. AM has more side effects and its effect on insomnia may diminish after tapering. CBT-I should remain first-line treatment for patients with medical comorbidity given its broader benefits.
- 26 June 2025
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 48 (12)
Open AccessLow dose amitriptyline versus cognitive behavioral therapy for insomnia in patients with medical comorbidity: results of a randomized controlled multicenter non inferiority trial
Study objectives: In a randomized controlled non-inferiority trial, we aimed to determine whether low dose Amitriptyline (AM), which is often used off-label, is a safe and effective alternative to cognitive behavioral therapy for insomnia (CBT-I) in the treatment of insomnia among patients with insomnia and medical comorbidity. Methods: A total of 187 participants with insomnia and medical comorbidity were randomly allocated to either: 1) 12 weeks of AM, 10-20 mg (n = 93), or 2) 12 weeks of group CBT-I, 7 sessions (n = 94). Assessments took place at baseline, 6 and 12 weeks after start of treatment. The primary non-inferiority outcome was insomnia severity (Insomnia Severity Index; ISI) at 12 weeks. Results: Based on a non-inferiority margin of four points on the ISI, AM was non-inferior to CBT-I at 12 weeks of treatment (mean difference of 1.1 points; 95% CI -0.5 to 2.8). Secondary analyses showed that significantly more CBT-I participants reached a clinical response (≥ 8-point reduction on the ISI) than AM participants (58% versus 41%, p=.02). AM participants reported more side-effects (mostly anticholinergic) at 12 weeks treatment (p<.001) than participants who received CBT-I. After discontinuation 68% of the AM participants reported worsening of sleep. In 12% of them this worsening was temporarily. Conclusions: With a liberal non-inferiority margin, AM is non-inferior to CBT-I in reducing insomnia severity. AM has more side effects and its effect on insomnia may diminish after tapering. CBT-I should remain first-line treatment for patients with medical comorbidity given its broader benefits.